Quick Answer
Aspire Biopharma Holdings, Inc. reported Total Assets of $1.31 million for the year ending 2025.
- Aspire Biopharma Holdings, Inc. showed an increase of +786.7% in Total Assets from 2024 to 2025.
- This data is from Aspire Biopharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $296.50 million | Q2 2022: $296.72 million | Q3 2022: $297.84 million | Q1 2023: $303.11 million | Q2 2023: $20.56 million | Q3 2023: $19.89 million | Q1 2024: $20.20 million | Q2 2024: $6.87 million | Q3 2024: $6.66 million | Q1 2025: $1.97 million | Q2 2025: $989.4 thousand | Q3 2025: $2.40 million.
- Over the full 5 years of available data (2021 to 2025), Aspire Biopharma Holdings, Inc.'s Total Assets has grown by 347.5%.
- Historical annual values: Fiscal year 2025: $1.31 million | Fiscal year 2024: $148.0 thousand | Fiscal year 2023: $19.98 million | Fiscal year 2022: $300.18 million | Fiscal year 2021: $293.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: